Antoine Angelergues

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · New England Journal of Medicine · 2023 · 316 citations · Full text

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 116 citations · Full text

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Antoine Angelergues, Denis Maillet, Aude Fléchon et al. · European Journal of Cancer · 2014 · 53 citations

Urology, Oncology, Genitourinary Cancer +7

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2023 · 50 citations

Cancer Management, Immunology, Pathology +18